Jump to content
Objectivism Online Forum
Sign in to follow this  


Rate this topic

Recommended Posts

Adult stem cells show enormous theraputic potential for treating a large number of degenerative conditions. That promise is already being realized in several other countries whose governments are less hostile to biotech innovation, but in the U.S., their use remains utterly encumbered by the regulatory environment here. As a result, the U.S. is underperforming third-world shitcans like Mexico and Thailand in this vital new arena. To my amazement, Senator Mark Kirk (R-Ill), with a Democrat co-sponsor, recently introduced a bill titled the REGROW Act that would drastically reduce the regulatory barriers to patient access of regenerative medicine products. It would create an altogether new regulatory pathway for cell-based products, which, among other things, would include a 5-year "conditional approval" policy that would allow these treatments to be used immediately if they show strong prima facie evidence of safety and effectiveness. This would be a game-changer for the U.S. healthcare if it passes, which is why I'm thinking it won't. It's contradictory to the spirit of ObamaCare, with its reliance on strict government-imposed treatment guidelines, and I can't see the same people who had to cram the law down our throats so we could see what's in it supporting a law like this. 



Edited by dream_weaver

Share this post

Link to post
Share on other sites

Create an account or sign in to comment

You need to be a member in order to leave a comment

Create an account

Sign up for a new account in our community. It's easy!

Register a new account

Sign in

Already have an account? Sign in here.

Sign In Now
Sign in to follow this  

  • Recently Browsing   0 members

    No registered users viewing this page.